Recursion Pharmaceuticals, Inc. (RXRX)
3.25
-0.12
(-3.56%)
USD |
NASDAQ |
Mar 20, 16:00
3.25
0.00 (0.00%)
After-Hours: 20:00
Recursion Pharmaceuticals Research and Development Expense (Quarterly) : 83.34M for Dec. 31, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Intellia Therapeutics, Inc. | 86.27M |
| Tango Therapeutics, Inc. | 31.62M |
| Hims & Hers Health, Inc. | 40.96M |
| Novavax, Inc. | 73.98M |
| Geron Corp. | 15.83M |